Newsroom

News

  • Qima Life Sciences gives an oral presentation entitled “IL-15 contributes to atopic dermatitis pathogenesis: lessons from a novel humanized mouse disease model”. In this model, CALY-002 anti-IL-15 antibody demonstrated efficacy across multiple clinical, histological and immunological endpoints.

  • Jos Houbiers, CMO of Calypso Biotech, gives an oral presentation entitled: “Interim resuts from a first-in-human study of the anti-IL-15 antibody CALY-002 for treating Celiac Disease and Eosinophilic Esophagitis”.

  • Calypso Biotech and Qima Life Sciences presents a poster entitled “IL-15 contributes to atopic dermatitis pathogenesis: lessons from a novel humanized mouse disease model”. In this model, CALY-002 anti-IL-15 antibody demonstrated efficacy across multiple clinical, histological and immunological endpoints.

  • 19th International Celiac Disease Symposium, Sorrento, Italy. Jos Houbiers, Chief Medical Officer of calypso Biotech, gives a lecture entitled “Interim results from an in-human study of an anti-IL-15 antibody for treating celiac disease”